Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer: A Phase 3 Randomized Clinical Trial

医学 帕妥珠单抗 内科学 乳腺癌 肿瘤科 卡铂 曲妥珠单抗 临床终点 新辅助治疗 随机对照试验 阶段(地层学) 临床试验 化疗 激素受体 乳房外科 激素疗法 保乳手术 癌症 激素疗法 疾病 紫杉烷 荟萃分析 佐剂 临床研究阶段
作者
Junjie Li,Tong Liu,Ke‐Da Yu,Huawei Yang,Zhen Huang,Yi Zeng,Peng Ji,Xiaoke Hou,Chunping Liu,Yiwen Zhang,Nanlin Li,Zhong Ouyang,Xiaobo Wu,Xiaorong Bai,Yanxiang Guo,Guohui Han,Shien Cui,Zhijun Zhu,Yu Zhang,Xiaobo Hu
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:12 (11): 1218-1218 被引量:3
标识
DOI:10.1001/jamaoncol.2026.3329
摘要

IMPORTANCE: The combination of neoadjuvant taxanes with trastuzumab and pertuzumab remains the cornerstone treatment strategy in ERBB2-positive breast cancer. Anbenitamab (a ERBB2-biparatopic antibody that induces profound receptor clustering) and HB1801 (a solvent-free albumin-bound docetaxel), have shown promising antitumor activity and an acceptable safety profile in patients with breast cancer. OBJECTIVE: To evaluate whether neoadjuvant anbenitamab combined with HB1801 could improve efficacy without increasing toxic effects for patients with early ERBB2-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 3 registrational randomized clinical trial enrolled patients with stage II or III ERBB2-positive breast cancer from 61 hospitals in China between December 19, 2024, and August 29, 2025 (data cutoff: January 28, 2026). Data were analyzed from February 1 to March 20, 2026. INTERVENTIONS: Patients were randomly assigned (1:1) to receive 6 cycles of neoadjuvant anbenitamab plus HB1801, with or without carboplatin (investigational group), or trastuzumab, pertuzumab, and docetaxel, with or without carboplatin (control group). MAIN OUTCOMES AND MEASURES: The primary end point was total pathological complete response (tpCR) assessed by a blinded independent review committee. RESULTS: Among 521 included patients (median [IQR] age, 52.0 [23-79] years), 263 were randomized to the investigational group and 258 to the control group. The tpCR rate was significantly higher in the investigational group than the control group (164 patients [62.4%] vs 132 patients [51.2%]; absolute difference, 11.4 [95% CI, 3.2 to 19.6] percentage points; P = .004). Benefit was consistent across subgroups, including subgroups with hormone receptor-positive disease (77 patients [51.7%] vs 63 patients [44.4%]), hormone receptor-negative disease (87 patients [76.3%] vs 69 patients [59.5%]), early-stage disease (111 patients [63.8%] vs 87 patients [51.8%]), locally advanced disease (53 patients [59.6%] vs 45 patients [50.0%]), with carboplatin treatment (74 patients [66.7%] vs 61 patients [54.5%]), and without carboplatin treatment (90 patients [59.2%] vs 71 patients [48.6%]). Grade 3 or 4 treatment-related adverse events occurred in 77 patients (29.3%) in the investigational group and 73 patients (28.3%) of the control group. No treatment-related deaths occurred. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that neoadjuvant anbenitamab and HB1801 in patients with breast cancer significantly improved the tpCR rate compared with standard therapy with a highly manageable safety profile. This new combination may offer an improved treatment option, although long-term survival follow-up analyses are warranted. Trial Registration: ClinicalTrials.gov Identifier: NCT06747338.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被无奈醉柳采纳,获得10
2秒前
酷波er的应助被昔我往矣采纳,获得10
2秒前
骨精龙人完成签到,获得积分10
2秒前
顺利毕业发布了新的文献求助10
2秒前
Maestro_S的应助被简简单单采纳,获得50
3秒前
FashionBoy的应助被冷静映易采纳,获得10
3秒前
慕容真完成签到,获得积分10
4秒前
科研通AI6.3的应助被强强采纳,获得10
4秒前
ding的应助被尘南浔采纳,获得10
5秒前
dmy完成签到 ,获得积分10
5秒前
6秒前
想读书完成签到,获得积分10
6秒前
今后的应助被ZRH采纳,获得10
6秒前
Lucas的应助被林洁佳采纳,获得10
8秒前
SciGPT的应助被Silica1004采纳,获得20
8秒前
8秒前
汤姆逊波纹疾走完成签到,获得积分10
9秒前
10秒前
10秒前
Felix发布了新的文献求助10
11秒前
李爱国的应助被tongtong采纳,获得10
12秒前
隐形曼青的应助被鳗鱼元正采纳,获得10
13秒前
14秒前
DXL发布了新的文献求助10
14秒前
星辰大海的应助被wx采纳,获得10
14秒前
Mayday完成签到,获得积分10
15秒前
共享精神的应助被董梓轩采纳,获得10
15秒前
科研通AI6.4的应助被XIAOGONG采纳,获得10
15秒前
科研通AI6.3的应助被u806686采纳,获得10
15秒前
wuwui发布了新的文献求助10
16秒前
17秒前
17秒前
丁香鱼完成签到,获得积分10
18秒前
jzt12138完成签到,获得积分10
18秒前
yyz完成签到,获得积分10
18秒前
葡萄的应助被bigpluto采纳,获得10
19秒前
20秒前
cc发布了新的文献求助10
20秒前
21秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193605
求助须知:如何正确求助?哪些是违规求助? 9579751
关于积分的说明 21867369
捐赠科研通 7793242
什么是DOI,文献DOI怎么找? 3437325
关于科研通互助平台的介绍 2560761
邀请新用户注册赠送积分活动 2484193